• 12 July, 2016
    Biosimilar Bevacizumab for Metastatic Colorectal Cancer Launched in India

    One of the generic Indian pharmaceutical companies, Hetero Drugs has launched a biosimilar for the treatment of metastatic colorectal cancer (mCRC) in India.

    The drug called as "Bevacizumab" has been approved by the Drug Controller General of India as the first-line of treatment for this type of cancer and will be marketed under the brand name 'cizumab'.

    ‘Hyderabad-based pharmaceutical company Hetero Drugs has launched its biosimilar 'Bevacizumab' for the treatment of metastatic colorectal cancer in India. ’

    The product will be available in a single dose vial with two strengths, 100 and 400mg. Hetero will manufacture the drugs in the facility based in Hyderabad. 

    Dr BPS Reddy, CMD, Hetero Group of Companies said: "It has been an exciting journey for us in Biologics. Hetero's Bevacizumab is the third product in our biologics portfolio, after Darbepoetin alfa and Rituximab. We believe CizumabTM will be a cost-effective treatment option to patients in India."


Latest News

02 March 2017

Sex-Change Surgery: India\'s New Line In Budget Medical Tourism

After decades of battling depression, former soldier Betty Ann Archer finally flew to New Delhi to complete her gender transition, one of a growing number of foreigners heading to India for budget sex-change operations. Born Dale Archer, the 64-year-old American said she felt trapped in the wrong body right from the start, recalling secretly trying on her mother\'s dresses as a boy -- much to the horror of her conservative military father. \"I attempted to kill myself twice...

Our Associations

We're Online